| Old Articles: <Older 6841-6850 Newer> |
|---|
 |
The Motley Fool
October 27, 2010
Travis Hoium |
Amylin Pharmaceuticals Shares Popped: What You Need to Know Amylin Pharmaceuticals shares bounced 10% today on an upgrade from analysts at Leerink Swann.   |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
The Motley Fool
October 26, 2010
Selena Maranjian |
Make Money in Biotech the Simple Way These ETFs present an easy way to invest in biotechnology. |
The Motley Fool
October 26, 2010
Brian Orelli |
Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs. |
The Motley Fool
October 26, 2010
Ralph Casale |
Where We Are in the War on Cancer A summary of the roundtable discussions at Xconomy's recent event, "Boston's War on Cancer." |
The Motley Fool
October 26, 2010
Brian Orelli |
Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth. |
The Motley Fool
October 26, 2010
Travis Hoium |
ARIAD Pharmaceuticals Shares Plunged: What You Need to Know A day after shares pop, the company announced a stock offering at $3.70 per share, and shares drop. |
The Motley Fool
October 26, 2010
Seth Jayson |
From Gross to Net at Gilead Sciences Here's the margin picture for Gilead Sciences over the past few years. |
The Motley Fool
October 25, 2010
Rich Smith |
GE: $5 Billion Down, $25 Billion to Go GE spends, but not wisely. |
The Motley Fool
October 25, 2010
Brian Orelli |
Arena's Boring News The Food and Drug Administration turned down Arena Pharmaceuticals' obesity drug, lorcaserin. Tell us something we didn't know. |
| <Older 6841-6850 Newer> Return to current articles. |
